SCHEMBL6403668

SCHEMBL6403668

CC(C)(C)c1cc(COC(=O)O)cc(C(C)(C)C)c1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 6/20 0.53
ALDH1A1 P00352 5/20 0.53
TSHR P16473 3/20 0.53
LMNA P02545 3/20 0.53
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
MAPK1 P28482 2/20 0.49
BLM P54132 2/20 0.49
ATM Q13315 2/20 0.49
HIF1A Q16665 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
USP2 O75604 1/20 0.49
CYP2D6 P10635 1/20 0.49
MAPT P10636 1/20 0.49
GABBR2 O75899 2/20 0.47
GABBR1 Q9UBS5 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
GMNN O75496 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6403664 0.86 ALDH1A1 (0.49) GAAALDH1A1TSHRLMNAKMT2A
SCHEMBL931514 0.86 ALDH1A1 (0.51) GAAALDH1A1TSHRLMNAKMT2A
SCHEMBL3125768 0.84 GAA (0.50) GAAALDH1A1TSHRLMNAKMT2A
SCHEMBL11492567 0.84 ALDH1A1 (0.47) GAAALDH1A1TSHRLMNAKMT2A
SCHEMBL5012328 0.84 ALDH1A1 (0.47) GAAALDH1A1TSHRLMNAKMT2A
SCHEMBL9015587 0.84 ALDH1A1 (0.47) GAAALDH1A1TSHRLMNAKMT2A
SCHEMBL6473822 0.84 ALDH1A1 (0.47) GAAALDH1A1TSHRLMNAKMT2A
SCHEMBL3125775 0.83 GAA (0.47) GAAALDH1A1TSHRLMNAKMT2A
SCHEMBL6696308 0.83 ALDH1A1 (0.46) GAAALDH1A1TSHRLMNAKMT2A
SCHEMBL28850429 0.83 HMGCR (0.49) GAAALDH1A1TSHRLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6867297-B1 Process for synthesizing 4-substituted azetidinone derivatives DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2005-03-15 US disclosed
US-20050004092-A1 Penem derivatives and antimicrobial agent containing the same DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2005-01-06 US disclosed
EP-0757051-B1 PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME DAIICHI SUNTORY PHARMA CO LTD (JP) 2003-10-29 EP disclosed
EP-0638552-B1 PROCESS FOR SYNTHESIZING 4-SUBSTITUTED AZETIDINONE DERIVATIVE DAIICHI SUNTORY PHARMA CO LTD (JP) 2003-06-04 EP disclosed
US-6051569-A 1'S, 5R, 6R-carbapenem derivatives and antimicrobial agents comprising the same SUNTORY LIMITED (JP) 2000-04-18 US disclosed
EP-0826687-A1 Carbapenem derivatives and antimicrobial agents comprising the same SUNTORY LIMITED (JP) 1998-03-04 EP disclosed
EP-0774465-A1 Penem derivatives and antimicrobial agents containing the same SUNTORY LIMITED (JP) 1997-05-21 EP disclosed
EP-0757051-A1 PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME SUNTORY LIMITED (JP) 1997-02-05 EP disclosed
EP-0638552-A1 PROCESS FOR SYNTHESIZING 4-SUBSTITUTED AZETIDINONE DERIVATIVE SUNTORY LIMITED (JP) 1995-02-15 EP disclosed
EP-0174277-B1 ANTI-OXIDANT COMPOSITONS FOR ORGANIC MATERIAL CIBA-GEIGY AG (CH) 1988-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004092-A1 Penem derivatives and antimicrobial agent containing the same MRPL21, MRPS2, MRPS28 GAA 2407/4885ALDH1A1 1862/4885TSHR 2489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.